Bangladesh High Commissioner in Pakistan Shorab Hussain on Friday said the second “Made in Pakistan” exhibition, which is likely to be held in last week of current month in Bangladesh, will prove beneficial for boosting trade ties between the two countries.
He said this talking to President of Rawalpindi Chamber of Commerce Industry (RCCI) Jawad Akhtar Bhatti, who called on him. Shorab Hussain appreciated RCCI for playing a key role in further strengthening the trade ties between the two countries and said holding of such exhibitions should be a regular feature, said a press release issued by RCCI. The commissioner said long term strategy should be devised to achieve the desirable results in the field of economy for the benefit of the two countries. He said the first single country exhibition held in Dhaka last year provided opportunities to traders of both the countries to interact with each and share their expertise. It also helped in assessing the market-based requirements for doing business.
He suggested starting shipping serving between the two countries as it would help curtail transportation charges, bringing product prices down for mutual benefit of people of the two countries. President of RCCI said the existing trade volume between the two countries is around $ 757 million which is insufficient. The objective behind holding ‘Made in Pakistan’ exhibition in Bangladesh is to promote bilateral trade ties between the two countries and to open up new avenues for the promotion of business activities.Sources in RCCI told APP that holding of the second exhibition in Bangladesh is part of the chamber’s consistent efforts to further promote local products in international markets. The exhibition is expected to be held in Bangladesh from May 22 to 27.
Bone drugs may not have long-term benefits: Long-term use of bone boosting drugs such as Fosamax may be less effective in reducing the risk of osteoporosis in post-menopausal women, a US study suggests.
The US Food and Drug Administration (FDA) says that more than three to five years use of a group of popular bone-strengthening drugs celled bisphosphonates provides little protection against bone fractures, Iranian Press TV reported.
The analysis of two previous studies involving 2,342 post-menopausal women “showed little benefit of continued bisphosphonate treatment beyond five years,” says the report published in the New England Journal of Medicine.
